Bonus Material-07_Ryu_Diffuse Parenchymal Lung Diseases 2025

Pdf Summary

This comprehensive presentation by Dr. Jay H. Ryu covers Diffuse Parenchymal Lung Diseases (DPLDs), also known as interstitial lung diseases (ILDs), a heterogeneous group of disorders affecting lung parenchyma. They represent about 10% of pulmonary diseases on certification exams and include idiopathic interstitial pneumonias (IIPs), sarcoidosis, systemic autoimmune-related ILDs (SARD/CTDs), granulomatous ILDs, smoking-related ILDs, and rare entities.<br /><br />Key learning objectives include understanding diagnostic approaches using clinical context, high-resolution CT (HRCT), bronchoalveolar lavage (BAL), biopsy, serologic tests, and multidisciplinary discussion (MDD). Diagnostic patterns on HRCT such as usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP) help classify IPF and other IIPs. Lung biopsy methods (forceps, cryobiopsy, surgical) vary in yield and risk.<br /><br />Idiopathic pulmonary fibrosis (IPF), a progressive fibrotic ILD with UIP pathology, presents with basal honeycombing and traction bronchiectasis. Diagnosis requires exclusion of other causes (environmental, drug, autoimmune). Treatment includes antifibrotics (pirfenidone, nintedanib) to slow lung function decline, supportive care, and early lung transplant referral. Acute exacerbations carry high mortality.<br /><br />Smoking-related ILDs include respiratory bronchiolitis-ILD, desquamative interstitial pneumonia, pulmonary Langerhans cell histiocytosis, and combined pulmonary fibrosis and emphysema (CPFE). Smoking cessation is essential.<br /><br />Systemic autoimmune diseases (SARDs), such as rheumatoid arthritis, systemic sclerosis, Sjögren’s, and antisynthetase syndrome, frequently cause ILD. Patterns vary and may respond to immunosuppression; antifibrotics are considered in fibrosis.<br /><br />Sarcoidosis is a multisystem granulomatous disease of unknown cause, diagnosed by compatible clinical-radiologic features and noncaseating granulomas, excluding infection and other causes. Pulmonary involvement is common, with lymphadenopathy and fibrotic stages. Treatment is often corticosteroids and immunosuppressants.<br /><br />Rare ILDs such as granulomatous lymphocytic ILD in common variable immunodeficiency (CVID) require immunoglobulin and immunosuppression.<br /><br />Overall, management is individualized based on disease subtype, severity, progression, underlying cause, and patient factors, with a multidisciplinary approach recommended.

Meta Tag

Concept Diffuse Parenchymal Lung Disease

Concept Interstitial Lung Disease

Concept High-Resolution Computed Tomography

Concept Idiopathic Pulmonary Fibrosis

Concept Usual Interstitial Pneumonia

Concept Sarcoidosis

Concept Smoking-Related Interstitial Lung Disease

Concept Systemic Autoimmune Rheumatic Disease

Concept CTD-ILD

Keywords

Diffuse parenchymal lung diseases

Interstitial lung disease

High-resolution CT

Idiopathic pulmonary fibrosis

Usual interstitial pneumonia

Nonspecific interstitial pneumonia

Antifibrotic therapy

Sarcoidosis

Systemic autoimmune-related ILD

Smoking-related ILD

Diffuse Parenchymal Lung Disease

Interstitial Lung Disease

High-Resolution Computed Tomography

Idiopathic Pulmonary Fibrosis

Usual Interstitial Pneumonia

Sarcoidosis

Smoking-Related Interstitial Lung Disease

Systemic Autoimmune Rheumatic Disease

CTD-ILD